aCoV™ is a novel biochemiluminescent, homogeneous assay that mimics the reaction process of firefly luminescence, making it an ideal assay for the quantitative detection of pathogens. By designing and synthesizing specific substrates derivatized with firefly luciferin or artificially modified luciferase mutants, this novel technology can be applied in various diagnostic areas, including bacterial vaginosis detection, influenza virus detection, and coronavirus detection.
By integrating bioluminescence technology with freeze-drying technology, smaller amounts of samples and reagents are required, resulting in accurate and sensitive test results. Furthermore, the signal intensity is expected to be proportional to the activity of the biochemiluminescent substrate, allowing for rapid and quantitative detection of pathogens in a short time. This is critical as it overcomes the limitations of many other types of assays, such as colorimetric assays, which have low sensitivity and cannot quantify samples.
aCoV™ technology involves two enzymatic reactions. In the first reaction, a substrate derivatized with firefly luciferin is cleaved to release luciferin. In the second reaction, firefly luciferase oxidizes the luciferin to generate a light signal. Alternatively, an artificially modified luciferase mutant can be used, which reacts with the target and releases luciferase to then oxidize luciferin and generate a light signal. Thanks to the exceptional sensitivity of aCoV™ technology, our aCoV™ test kits, when used alongside our cutting-edge Bioluminescence Analyzer AJX300, enable rapid detection times and straightforward result interpretation, ensuring precise and efficient analysis. Our aCoV™ kits and instruments are CE certified, demonstrating our commitment to quality and compliance with European Union regulations.